Xenetic Biosciences, Inc. (NASDAQ:XBIOW) Short Interest Down 50.0% in April

Xenetic Biosciences, Inc. (NASDAQ:XBIOW) saw a large drop in short interest during the month of April. As of April 15th, there was short interest totalling 200 shares, a drop of 50.0% from the March 31st total of 400 shares. Based on an average trading volume of 300 shares, the short-interest ratio is currently 0.7 days.

Xenetic Biosciences Price Performance

Shares of XBIOW stock opened at $7.46 on Friday. Xenetic Biosciences has a fifty-two week low of $0.70 and a fifty-two week high of $23.16. The stock’s 50-day simple moving average is $11.61 and its 200-day simple moving average is $8.08.

About Xenetic Biosciences

Xenetic Biosciences, Inc, a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer.